Table 2. The correlations between the clinicopathological factors and the area of tumor infiltrating lymphocytes.
| The density of TILs | |||
|---|---|---|---|
| High (N = 42) | Low (N = 118) | p-value | |
| Sex | |||
| Male | 19 (11.9%) | 65 (40.6%) | 0.2726 |
| Female | 23 (14.4%) | 53 (33.1%) | |
| Age (years) | |||
| Median(range) | 68 (34–89) | 65 (26–90) | 0.1594 |
| Tumor location | |||
| Colon | 22 (13.8%) | 64 (40.0%) | 0.8359 |
| Rectum | 20 (12.5%) | 54 (33.8%) | |
| Tumor size (cm) | |||
| Median(range) | 5.1 (1.0–10.0) | 4.5 (1.0–11.0) | 0.1874 |
| Depth of tumor invasion | |||
| T1,2,3 | 33 (20.6%) | 73 (45.6%) | 0.0435 |
| T4 | 9 (5.6%) | 45 (28.1%) | |
| Lymph node metastasis | |||
| Negative | 27 (16.9%) | 63 (39.4%) | 0.2187 |
| Positive | 15 (9.4%) | 55 (34.4%) | |
| Lymphatic vessel invasion | |||
| Negative | 15 (9.4%) | 23 (14.4%) | 0.0391 |
| Positive | 27 (16.9%) | 95 (59.4%) | |
| Venous invasion | |||
| Negative | 38 (23.9%) | 90 (56.6%) | 0.0135 |
| Positive | 3 (1.9%) | 28 (17.6%) | |
| Preoperative CEA level | |||
| ≤5 ng/ml | 30 (18.8%) | 73 (45.6%) | 0.2609 |
| >5 ng/ml | 12 (7.5%) | 45 (28.1%) | |
| Preoperative CA19-9 level | |||
| ≤ 37 U/ml | 39 (24.8%) | 99 (63.1%) | 0.2273 |
| >37 U/ml | 3 (1.9%) | 16 (10.2%) | |
| Histology | |||
| Moderately or Well | 40 (25.0%) | 107 (66.9%) | 0.3282 |
| Other | 2 (1.3%) | 11 (6.9%) | |
| Adjuvant chemotherapy | |||
| Negative | 15 (6.3%) | 41 (25.8%) | 0.8321 |
| Positive | 26 (16.4%) | 77 (48.4%) | |
| Mismatch repair status | |||
| Proficient | 40 (25.6%) | 107 (68.6%) | 0.7385 |
| Deficient | 2 (1.3%) | 7 (4.5%) | |
TILs, tumor infiltrating lymphocyte; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19–9.